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ABSTRACT
Recipients of kidney transplants (KTR) are at increased risk for cardiovascular events, graft failure, and death. It is
unknown whether urine kidney injury biomarkers are associated with poor outcomes among KTRs. We
conducted a post hoc analysis of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT)
Trial using a case-cohort study design, selecting participants with adjudicated cardiovascular events, graft failure,
or death. Urine neutrophil gelatinase–associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), IL-18, and
liver–type fatty acid binding protein (L-FABP) were measured in spot urine samples and standardized to urine
creatinine concentration.We adjusted for demographics, cardiovascular risk factors, eGFR, and urine albumin-to-
creatinine ratio. Patientshad291cardiovascular events, 257graft failureevents, and359deaths. Each log increase
in urine NGAL/creatinine independently associated with a 24% greater risk of cardiovascular events (adjusted
hazard ratio [aHR], 1.24; 95% confidence interval [95% CI], 1.06 to 1.45), a 40% greater risk of graft failure (aHR,
1.40;95%CI,1.16 to1.68), anda44%greater riskofdeath (aHR,1.44;95%CI,1.26 to1.65).UrineKIM-1/creatinine
and IL-18/creatinine independently associatedwithgreater riskof death (aHR, 1.29; 95%CI, 1.03 to1.61 andaHR,
1.25; 95%CI, 1.04 to 1.49 per log increase, respectively) but not with risk of cardiovascular events or graft failure.
Urine L-FABP did not associate with any study outcomes. In conclusion, among prevalent KTRs, higher urine
NGAL, KIM-1, and IL-18 levels independently and differentially associatedwith greater risk of adverse outcomes.
J Am Soc Nephrol 27: 2109–2121, 2016. doi: 10.1681/ASN.2015030292
Despite improvements in short–termpatient andgraft
outcomes, long–term clinical outcomes of recipients
of kidney transplants (KTRs) remain suboptimal.1,2
The leading cause of death in KTRs is cardiovascular
disease (CVD), and KTRs also have significant risk of
long–term graft failure.1 Identification of biomarkers
that are independent risk factors for adverse outcomes
may provide insight into underlying pathophysiologic
mechanisms relevant to KTRs.
Urine biomarkers of kidney tubular injury have
been studied in patients with native CKD3,4 and the
general population.5–7 A number of these bio-
markers, including neutrophil gelatinase–associated
lipocalin (NGAL), kidney injury molecule-1
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(KIM-1), IL-18, and liver–type fatty acid binding protein
(L-FABP), were initially described in patients with acute tu-
bular necrosis/AKI.8–11 NGAL is a 25-kD protein expressed
in the kidney, liver, and epithelial cells in response to various
pathologic states, such as inflammation, infection, intoxica-
tion, ischemia, AKI, and neoplastic transformation.12 NGAL
is filtered in the glomerulus, and luminal NGAL is reabsor-
bed in the proximal tubule. In the setting of kidney injury,
proximal tubule reabsorption of systemically produced
NGAL is impaired, and NGAL production is increased in
the distal nephron and shed into the urine, leading to higher
urine NGAL levels.13,14 Urine KIM-1 is a phosphatidylserine
receptor that recognizes apoptotic cells, directing them to
lysosomes, and it also serves as a receptor for oxidized lipo-
proteins.15–17 KIM-1 transforms kidney proximal epithelial
cells into phagocytes and may act to modulate immune re-
sponse in kidney injury.16,17 IL-18 is a known mediator of
inflammation and found in monocytes, fibroblasts, and
proximal renal tubular epithelial cells.18,19 IL-18 mediates
ischemic proximal tubule injury and proinflammatory re-
sponses through its actions on Toll-like receptor 4.20 L-FABP
expression and urinary excretion increase under condi-
tions of tubular stress. It is hypothesized that free fatty
acids, which are, in part, albumin bound, exert oxidative
stress on cells and that L-FABP inhibits the accumula-
tion of intracellular fatty acids by promoting fatty acid
metabolism.21–24
Among KTRs, previous studies have shown strong asso-
ciations of serum creatinine and albuminuria with poor
clinical outcomes, similar to patients with native CKD.
Numerous studies in patients with CKD have recently
suggested that, independent of serum creatinine, eGFR,
and levels of albuminuria, tubular injury markers are risk
factors for adverse outcomes, such as kidney failure, death,
and CVD.3,4,6,25–28 It has been suggested that GFR and albu-
minuria mostly reflect glomerular disease, whereas these in-
jury biomarkers reflect renal tubular disease. Published
studies of urine injury biomarkers among KTRs largely
have been limited to the peritransplant setting and focused
on associations with short-term outcomes, such as delayed
graft function or in-hospital mortality.29–33 It is plausible
that these biomarkers of tubular injury or stress may signal
earlier systemic disease or graft disease that contributes to
adverse cardiovascular or renal outcomes among KTRs. We
studied the associations of urine NGAL, KIM-1, IL-18, and
L-FABP with long–term adverse outcomes, including car-
diovascular events, graft failure, and all-cause mortality,
among prevalent KTRs enrolled in the Folic Acid for Vascu-
lar Outcome Reduction in Transplantation (FAVORIT)
Trial, a randomized clinical trial of homocysteine lowering
by B vitamins. We hypothesized that, similar to patients
with native kidney disease,3,4 elevations in these urine in-
jury biomarkers would be associated with poor clinical
outcomes among KTRs, independent of traditional kidney
measures.
RESULTS
Participant Characteristics
The mean age (6SD) of the random subcohort was 51 (69)
years old, and eGFR was 46 (618) ml/min per 1.73 m2. Median
(interquartile range) urine albumin-to-creatinine ratio (ACR)
was 24.5 (9.5–104.7) mg/mg, urine NGAL was 20.2 (8.2–51.3)
ng/ml, urine KIM-1 was 658 (319–1364) pg/ml, urine IL-18 was
29.1 (11.5–62.5) pg/ml, and urine L-FABP was 6.1 (3.0–17.6)
ng/ml (Supplemental Table 1, column 1). Participants with the
highest quartile of urineNGAL/creatinine weremore likely to be
women, have a lower eGFR, and have a higher urine ACR (Sup-
plemental Table 1a). Participants with the highest quartile of
urine KIM-1/creatinine were more likely to be women and
have higher urine ACR and less likely to have received a living
donor kidney (Supplemental Table 1b). Participants with the
highest quartile of urine IL-18/creatinine were more likely to
be women and have higher urine ACR. Graft vintage was longer
among participants in the lowest quartile of urine IL-18/creati-
nine, and the biomarker distributions differed by country (Sup-
plemental Table 1c). Participants with the highest quartile of
urine L-FABP/creatinine were more likely to use sirolimus and
have higher BP, lower eGFR, and higher urineACR (Supplemen-
tal Table 1d). Overall, only 3% of KTRs (16 of 489 from the
random subcohort) were in the highest quartile of all four urine
biomarkers (as illustrated in Figure 1, with the Venn diagram
showing overlap).
Participantswhohad a cardiovascular event or a graft failure
ordiedweremore likely tobe fromtheUnitedStates, haveolder
Figure 1. Only 3% of KTRs were in the highest quartile of all four
urine biomarkers. Venn diagram of the overlap of the top quartile
of urine NGAL/creatinine, KIM-1/creatinine, IL-18/creatinine, and
L-FABP/creatinine in the subcohort (n=489).
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graft vintage, have higher systolic BP, have lower eGFR, and
have higher urine ACR (Table 1).
Correlations among Measures of Kidney Function and
Urine Injury Biomarkers
Among participants in the subcohort, eGFR level was nega-
tively correlated with urine NGAL and urine L-FABP (Sup-
plemental Figure 1, Table 2). Urine albumin was positively
correlated with all four biomarkers. There were moderately
strong positive correlations among urine NGAL, KIM-1, IL-18,
and L-FABP; the strongest correlationwas between urine NGAL
and L-FABP (correlation coefficient =0.47; P,0.001) (Supple-
mental Figure 1, Table 2).
Urine Injury Biomarkers and Risk of Cardiovascular
Events
Overall mean follow-up time was 3.9 (61.6) years. Among par-
ticipants in the subcohort, the crude event rate was 2.7 per
100 person-years for cardiovascular events. The cumulative in-
cidence of cardiovascular events was greater for participants in
the highest quartile of urine NGAL/creatinine, KIM-1/creatinine,
and L-FABP/creatinine but not IL-18/creatinine and seemed
fairly constant over the follow-up period (Figure 2).
In the full study population, in unadjusted analyses, there
was a statistically significant association of urine NGAL/
creatinine, urine KIM-1/creatinine, and urine L-FABP/
creatinine (but not IL-18/creatinine) with risk of cardiovascular
events (Table 3). These associations remained statistically sig-
nificant after adjustment for participant demographics and
other cardiovascular risk factors. With additional adjustment
for urine ACR, only the association between urine NGAL/
creatinine and cardiovascular events remained statistically sig-
nificant. For each log higher urine NGAL/creatinine, the risk of
cardiovascular events was 24% higher (adjusted hazard ratio
[HR], 1.24; 95% confidence interval [95% CI], 1.06 to 1.45)
(Table 3).
Table 1. Baseline participant characteristics by outcome in the case-cohort study
Characteristics
Cardiovascular Events Graft Failure All-Cause Death
Nonevents
(n=438)
Events
(n=291)
Nonevents
(n=439)
Events
(n=257)
Nonevents
(n=423)
Events
(n=359)
Age (yr) 51.168.9 54.669.3 51.769.2 49.468.5 50.768.7 55.969.6
Women 174 (40%) 100 (34%) 174 (40%) 90 (35%) 161 (38%) 133 (37%)
Race
White 328 (75%) 221 (76%) 338 (77%) 180 (70%) 317 (75%) 264 (74%)
Black 81 (18%) 54 (19%) 75 (17%) 60 (23%) 78 (18%) 72 (20%)
Other 29 (7%) 16 (5%) 26 (6%) 17 (7%) 28 (7%) 23 (6%)
Treatment group
High-dose vitamin 216 (49%) 147 (51%) 211 (48%) 135 (53%) 211 (50%) 180 (50%)
Low-dose vitamin 222 (51%) 144 (49%) 228 (52%) 122 (47%) 212 (50%) 179 (50%)
Location
United States 298 (68%) 233 (80%) 302 (69%) 217 (84%) 283 (67%) 287 (80%)
Canada 52 (12%) 35 (12%) 50 (11%) 26 (10%) 55 (13%) 36 (10%)
Brazil 88 (20%) 23 (8%) 87 (20%) 14 (5%) 85 (20%) 36 (10%)
Graft vintage (yr),
median (25th, 75th)
3.9 (1.8, 7.0) 4.4 (1.9, 7.9) 3.8 (1.7, 6.8) 5.0 (2.3, 8.5) 3.8 (1.8, 7.1) 4.4 (1.8, 7.9)
Living donor kidney 193 (44%) 95 (33%) 192 (44%) 82 (32%) 190 (45%) 102 (28%)
History of CVD 72 (16%) 122 (42%) 83 (19%) 60 (23%) 72 (17%) 121 (34%)
History of diabetes mellitus 147 (34%) 189 (65%) 162 (37%) 116 (45%) 141 (33%) 211 (59%)
Smoking
Never 214 (49%) 131 (45%) 218 (50%) 118 (46%) 218 (52%) 139 (39%)
Current 47 (11%) 40 (14%) 52 (12%) 43 (17%) 47 (11%) 51 (14%)
Former 177 (40%) 120 (41%) 169 (38%) 96 (37%) 158 (37%) 169 (47%)
Calcineurin inhibitor use 381 (87%) 265 (91%) 384 (87%) 232 (90%) 373 (88%) 316 (88%)
Sirolimus use 43 (10%) 25 (9%) 43 (10%) 23 (9%) 41 (10%) 41 (11%)
Systolic BP (mmHg) 134.7619.4 143.5620.8 134.8619.9 141.3619.1 135.4619.8 140.8619.9
Diastolic BP (mmHg) 79.5612.4 77.6612.6 78.9612.6 79.6611.7 79.8612.5 76.6612.5
BMI (kg/m2) 29.066.0 29.766.4 29.066.0 29.566.7 29.066.0 29.666.5
HDL cholesterol (mg/dl) 46.9614.4 44.9614.0 46.8613.6 45.3615.8 47.4614.7 44.7614.9
LDL cholesterol (mg/dl) 103.8632.3 98.3637.6 102.6632.4 107.9639.6 104.3632.6 99.7636.7
Triglycerides (mg/dl) 198.96133.9 211.46142.5 197.96127.4 219.86175.1 195.76127.6 221.36156.2
eGFR (ml/min per 1.73 m2)a 46.5617.6 44.1617.9 47.5617.5 38.7616.5 46.6617.9 44.3618.0
ACR (mg/mg),
median (25th, 75th)
22.3 (8.6, 97.5) 44.1 (13.6, 234.1) 20.5 (8.4, 81.9) 190.2 (42.6, 719.4) 21.2 (8.4, 95.6) 57.4 (14.8, 227.0)
aEstimated glomerular filtration rate as calculated by the CKD-EPI equation.
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When participants with prevalent CVD at study entry were
excluded, none of the urine biomarkers were associated with
risk of cardiovascular events (although the 95% CIs were
wider) (Supplemental Table 2).
Urine Injury Biomarkers and Risk of Graft Failure
Within the subcohort, the crude graft failure event rate was
2.7 per 100 person-years. The cumulative incidence of graft
failure was greatest among participants in the highest quartile
of each urine biomarker/urine creatinine (Figure 3).
Among participants in the full study population, in un-
adjustedmodels, there was a statistically significant association
of higher urine NGAL/creatinine, urine KIM-1/creatinine,
urine IL-18/creatinine, and urine L-FABP/creatinine with
increased risk of graft failure (Table 4). These associations
remained robust after adjustment for participant demograph-
ics and other risk factors. After adjustment for urine ACR,
only the association between urine NGAL/creatinine and graft
failure remained statistically significant. For each log increase
in urine NGAL/creatinine, there was a 40% (adjusted HR,
1.40; 95%CI, 1.16 to 1.68) higher risk of graft failure (Table 4).
Urine Injury Biomarkers and Risk of All-Cause Mortality
Within the subcohort, the crudemortality rate was 3.3 per 100
person-years. The cumulative incidence of all-cause mortality
was greatest among participants in the highest quartile of each
urine biomarker/creatinine (Figure 4).
Among participants in the full study population, in un-
adjusted analyses, all four urine injury biomarkers/creatinine,
considered as continuous measures or quartiles, were associ-
ated with an increased risk of all-cause mortality (Table 5).
These associations remained statistically significant after
adjustment for demographic characteristics and other
cardiovascular risk factors. After adjustment
for urine ACR, the associations of urine
NGAL/creatinine (HR, 1.44; 95% CI, 1.26 to
1.65 per log increase), urine KIM-1/creatinine
(HR, 1.29; 95% CI, 1.03 to 1.61 per log in-
crease), and urine IL-18/creatinine (HR,
1.25; 95% CI, 1.04 to 1.49 per log increase)
remained statistically significant (Table 5).
When participants with CVD at study
entrywereexcluded, inmultivariable analysis
including adjustment for urine ACR, the
association between NGAL/creatinine and
all-cause mortality remained statistically sig-
nificant but not for urine KIM-1/creatinine
or urine IL-18/creatinine (although the 95%
CIs were wider) (Supplemental Table 2).
Sensitivity Analyses: Analyses of Urine
Biomarkers Not Standardized to Urine
Creatinine
In the full study population, in multivariable
models that examined raw urine biomarker
concentrations (i.e., not standardizing them to urine creati-
nine concentration) and after adjusted for urine ACR, urine
NGAL was associated with increased risk of cardiovascular
events, graft failure, and all-cause mortality(Supplemental
Table 3), similar to the main analysis (Tables 3–5). In multi-
variable models, urine IL-18 was significantly associated with
increased risk of all-cause mortality (Supplemental Table 3),
similar to the main analysis, whereas the association between
urine KIM-1 and mortality was attenuated and no longer sta-
tistically significant (Supplemental Table 3).
Sensitivity Analyses: Composite Outcomes
To assess whether our conclusions regarding cardiovascular
events or graft failure could be biased by competing risk of
death, we repeated our multivariable models examining two
composite outcomes: cardiovascular events or all-cause mor-
tality andgraft failureorall-causemortality.Overall, reassuring
results were obtained (Supplemental Table 4).
Post Hoc Exploratory Analyses: Interactions by Sex
Given the substantial differences in biomarker levels in men
and women (Supplemental Table 1), we tested for interaction
by sex in exploratory post hoc analyses. Across four biomarkers
and three outcomes, we found a statistically significant inter-
action by sex only in the association of IL-18/creatinine with
all-cause death (P value =0.01). In stratified analyses, the as-
sociation was stronger in men.
DISCUSSION
In prevalent KTRs, urine tubular injury biomarkers are asso-
ciated with greater risk of adverse cardiovascular outcomes,
Table 2. Spearman correlations of eGFR and urine biomarkers in a random
subcohort (n=489)
Kidney/Urine
Measure
Urine Albumin
(mg/dl)
Urine NGAL
(ng/ml)
Urine KIM-1
(pg/ml)
Urine IL-18
(pg/ml)
Urine L-FABP
(ng/ml)
eGFR (ml/min
per 1.73 m2)
Rho 20.17 20.21 20.02 0.02 20.21
P value ,0.001 ,0.001 0.64 0.69 ,0.001
Urine albumin
(mg/dl)
Rho 0.39 0.42 0.29 0.62
P value ,0.001 ,0.001 ,0.001 ,0.001
Urine NGAL (ng/ml)
Rho 0.36 0.42 0.47
P value ,0.001 ,0.001 ,0.001
Urine KIM-1 (pg/ml)
Rho 0.35 0.39
P value ,0.001 ,0.001
Urine IL-18 (pg/ml)
Rho 0.35
P value ,0.001
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graft failure, and all-cause mortality. Specifically, elevations
in urine NGAL/creatinine were significantly associated with
higher risk of cardiovascular events as well as increased risk
of graft failure. Furthermore, elevations in urine NGAL/
creatinine, KIM-1/creatinine, and IL-18/creatinine were associ-
ated with greater risk of all-cause mortality, with urine NGAL/
creatinine being themost robust. The observed associations were
independent of known cardiovascular risk factors as well
as established markers of kidney disease, including eGFR and
urine ACR. Our study suggests that urine injury markers may
signal early biologic injury that may contribute to higher risk of
adverse outcomes among prevalent KTRs.
Among the FAVORIT Trial participants that we studied
(median graft vintage of 3.8 years), levels of urine injury
biomarkers were moderately elevated, although overall, bio-
marker levels (not standardized to urine creatinine) were
several magnitudes lower than those seen in patients with AKI
after cardiac surgery10 or the immediate perikidney transplant
setting.29 For example, in a study of KTRs, urine NGAL and
IL-18 were markedly higher in the first 48 hours after kidney
transplant in those who developed delayed or slow graft func-
tion compared with our patient population.29 Interestingly,
among participants who had immediate graft function, urine
NGAL on the second postoperation day was similar to levels
Figure 2. Cumulative incidence of CVD events were higher among participants in the highest quartile of urine NGAL, KIM-1 and
L-FABP. Cumulative incidence of cardiovascular events by quartiles of (A) urine NGAL/creatinine, (B) urine KIM-1/creatinine, (C) urine
IL-18/creatinine, and (D) urine L-FABP/creatinine in a random subcohort (n=489).
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seen among prevalent KTRs in our study.29 The levels of
urine injury biomarkers seen in prevalent KTRs are similar
to those reported in studies of the general CKD population4
or a community–based elderly study population.5 For exam-
ple, urine NGAL levels at baseline among participants in the
Chronic Renal Insufficiency Cohort (CRIC) Study, an obser-
vational cohort study of persons with CKD (mean eGFR of
44 ml/min per 1.73 m2), were similar to levels that we observed
amongour studyof prevalentKTRs (mean eGFRof subcohort of
46 ml/min per 1.73 m2).4
In multivariable models, we found that urine NGAL was
significantly associated with higher risk of atherosclerotic
cardiovascular events. A similar association was not observed
for KIM-1, IL-18, or L-FABP when adjustment for urine ACR,
in particular, attenuated associations between biomarkers and
adverseoutcomes.Consistentwithourfindings, a recent report
from the CRIC Study showed a significant association of urine
NGAL with atherosclerotic cardiovascular events.4 Another
study of patients with CKD also noted a .3-fold higher risk
of cardiovascular events among those with the highest urine
NGAL levels.26 Also, similar to our findings, a study of older
adults reported no association of urine KIM-1 or IL-18 with
risk of CVD.5 Althoughwe did not find an association between
urine L-FABP and cardiovascular events, a prior study noted a
strong association among patients with type 2 diabetes.34 Un-
like the other urine injury biomarkers, urine NGAL is filtered
through the glomerulus and thus, may reflect more systemic
processes, including inflammation, which may possibly ex-
plain the association with atherosclerotic CVD.
Of four urine injury biomarkers that we investigated, only
urine NGAL was significantly associated with higher risk of
graft failure among prevalent KTRs. A prior study of prevalent
KTRs also noted an association of urine NGAL with graft
failure.35 Among incident KTRs in the peritransplant setting,
multiple urine injury biomarkers have been associated with
both delayed graft function29,30,36 and ESRD after 1 year.36
The associations of these urine injury biomarkers with kidney
outcomes in the nontransplant CKD setting are conflict-
ing.6,37–44 Similar to our findings, among patients with native
CKD, elevated urine NGAL has been shown to be significantly
associated with progression of CKD or incident ESRD.3,45,46
Some studies39 but not all6 have also noted associations of
higher urine NGAL with incident CKD. For example, among
high–risk American Indians with type 2 diabetes, elevations in
urine NGALwere significantly associated with risk of ESRD.40
However, these findings were not observed among persons
with type 1 diabetes.42,43 We did not find an association be-
tween urine KIM-1 and graft failure. Although some studies
have concluded that urine KIM-1 was an independent risk
factor for more rapid loss of renal function,6 others have
not.39,40,42,43 With regard to IL-18, there have been relatively
fewer studies of this biomarker. A prior study of HIV-infected
Table 3. Unadjusted and adjusted HR estimates for risk of cardiovascular events according to urine biomarker (n=780
participants)
Urine Biomarker Unadjusted HR (95% CI) Model 1 HR (95% CI) Model 2 HR (95% CI)
Urine NGAL/creatinine
Per log increase 1.23 (1.11 to 1.37)a 1.31 (1.13 to 1.52)a 1.24 (1.06 to 1.45)a
Quartile 1 Reference Reference Reference
Quartile 2 1.41 (0.91 to 2.19) 1.67 (0.97 to 2.88) 1.52 (0.87 to 2. 63)
Quartile 3 1.48 (0.96 to 2.28) 1.19 (0.64 to 2.20) 1.10 (0.59 to 2.05)
Quartile 4 2.05 (1.34 to 3.14)a 2.21 (1.21 to 4.05)a 1.79 (0.95 to 3.34)
Urine KIM-1/creatinine
Per log increase 1.33 (1.11 to 1.59)a 1.28 (1.03 to 1.58)a 1.14 (0.91 to 1.43)
Quartile 1 Reference Reference Reference
Quartile 2 1.21 (0.78 to 1.87) 1.40 (0.78 to 2.50) 1.21 (0.68 to 2.17)
Quartile 3 1.43 (0.93 to 2.20) 1.42 (0.80 to 2.52) 1.22 (0.69 to 2.17)
Quartile 4 1.83 (1.21 to 2.79)a 1.84 (1.06 to 3.18)a 1.39 (0.79 to 2.44)
Urine IL-18/creatinine
Per log increase 1.03 (0.91 to 1.16) 1.11 (0.93 to 1.32) 1.03 (0.86 to 1.23)
Quartile 1 Reference Reference Reference
Quartile 2 1.06 (0.71 to 1.60) 0.98 (0.58 to 1.65) 0.90 (0.53 to 1.53)
Quartile 3 1.17 (0.78 to 1.76) 1.61 (0.97 to 2.68) 1.36 (0.80 to 2.31)
Quartile 4 1.06 (0.69 to 1.63) 1.28 (0.68 to 2.43) 1.05 (0.55 to 1.99)
Urine L-FABP/creatinine
Per log increase 1.24 (1.10 to 1.39)a 1.17 (1.01 to 1.36)a 1.0 (0.83 to 1.20)
Quartile 1 Reference Reference Reference
Quartile 2 0.96 (0.62 to 1.48) 0.67 (0.36 to 1.24) 0.59 (0.32 to 1.11)
Quartile 3 1.64 (1.08 to 2.50)a 1.45 (0.85 to 2.48) 1.16 (0.66 to 2.03)
Quartile 4 1.73 (1.14 to 2.64)a 1.15 (0.67 to 1.98) 0.69 (0.36 to 1.30)
Model 1 was adjusted for demographics, treatment, country, history of CVD, diabetes, smoking, graft vintage, donor, BP, lipids, BMI, and eGFR. Model 2 was
adjusted for demographics, treatment, country, history of CVD, diabetes, smoking, graft vintage, donor, BP, lipids, BMI, eGFR, and urine ACR.
aChi-squared test: P,0.05.
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women found a strong independent association between
higher levels of urine IL-18 and risk of rapid decline in kidney
function,25 which is not what we observed. Finally, we did not
find an association between urine L-FABP and graft failure in
our study, although prior studies of persons with diabetes have
noted both inverse40 and linear associations between urine
L-FABP and risk of progression of CKD.34,41,47,48 Because rea-
sons for progressive loss of renal function after kidney trans-
plant likely include both traditional kidney disease risk factors
(such as elevated BP) as well as rejection/immunologic factors,
it is perhaps not surprising that findings among prevalent
KTRs would be different from nontransplant populations.
In our analysis of prevalent KTRs, we found a significant
association of urine NGAL, KIM-1, and IL-18 with risk of all-
cause mortality. Prior investigations have examined these
associations in select populations, yielding conflicting results.
For example, in the CRIC Study, urine NGAL was not
associated with all-cause mortality after multivariable adjust-
ment.4 Similarly, in a study of older men recruited from the
community, urine NGAL was associated with higher risk of
death in univariate analyses but not after multivariable adjust-
ment.49 In a study of American Indians, higher urine NGAL
but not KIM-1 was associated with increased risk of all-cause
mortality.40 Community-based studies have also noted
Figure 3. Cumulative incidence of graft failure was higher among participants in the highest quartile of urine injury biomarkers.
Cumulative incidence of graft failure by quartiles of (A) urine NGAL/creatinine, (B) urine KIM-1/creatinine, (C) urine IL-18/creatinine, and
(D) urine L-FABP/creatinine in a random subcohort (n=489).
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associations between elevated urine KIM-1 and higher risk of
all-causemortality.27,28We did not find an association of urine
L-FABP with all-cause mortality. Similar to other biomarkers,
the data on L-FABP and risk of mortality also have been con-
flicting. In HIV-infected women, a J-shaped association was
noted between urine L-FABP and risk of long-term mortal-
ity.50 In a study of persons with type 1 diabetes, a positive
association was found between L-FABP and risk of death.41
Thus, data from our study and others suggest that urine injury
biomarkers may have differential associations with risk of all-
cause death on the basis of the study population and acuity of
injury as well as the specific urine biomarker of interest.
It is interesting that, among the outcomes that we studied,
the highest HRs were seen for all-cause mortality, despite the
fact that the markers of kidney tubular injury are expressed
from a transplanted kidney. There are severe possible expla-
nations for these findings. First, these biomarkers may be
indicators of levels ordimensionsof kidney injurynot captured
by traditional markers of kidney function (e.g., serum creati-
nine and urine ACR). It is recognized that CKD is strongly
associated with all-cause mortality51,52; therefore, it is possible
that numerous different dimensions of kidney damage are risk
factors for mortality. For example, many important physio-
logic pathways are regulated by the kidney tubules, including
mineral metabolism, erythropoiesis, and acid-base regulation.
Therefore, tubular dysfunctionmay lead to alterations in these
important metabolic pathways, contributing to higher risk of
death.53 Second, these biomarkers may reflect systemic injury
from ischemia and other processes, which involve multiple
organs in parallel, ultimately contributing to higher risk of
death. For example, urine NGAL is thought to be a marker
of both kidney damage and systemic inflammation.12 Addi-
tional studies are needed to elucidate the precise mechanisms
to explain the observed associations.
Our study had several strengths. We studied a large, well
characterized, international cohort of prevalent KTRs with
rigorously adjudicated outcomes.We used a case-cohort study
design, which efficiently allowed us to study multiple impor-
tant clinical outcomes.Urine injurybiomarkersweremeasured
at a very experienced laboratory simultaneously from samples
that had not undergone a previous freeze-thaw cycle. We were
able to adjust for a substantial numberof possible confounders.
A few limitations should be noted as well. The FAVORIT Trial
did not collect biospecimens starting from the time of trans-
plant, and therefore, we could only study prevalent KTRs
(rather than longitudinal measures starting at the time of
surgerywhen injury is likely to bemaximal).Weonlyhad single
measures of each urine injury biomarker at study baseline. The
urine samples were collected from 2002 to 2007. Although we
used previously unthawed urine samples to measure our urine
biomarkers, it is unclear how age of the sample may have
affected the assays. Any nonspecific degradation would likely
Table 4. Unadjusted and adjusted HR estimates for risk of graft failure according to urine biomarker (n=744 participants)
Urine Biomarker Unadjusted HR (95% CI) Model 1 HR (95% CI) Model 2 HR (95% CI)
Urine NGAL/creatinine
Per log increase 1.58 (1.40 to 1.79)a 1.66 (1.42 to 1.94)a 1.40 (1.16 to 1.68)a
Quartile 1 Reference Reference Reference
Quartile 2 3.39 (1.99 to 5.77)a 3.48 (1.91 to 6.34)a 2.45 (1.26 to 4.76)a
Quartile 3 2.37 (1.37 to 4.09)a 2.22 (1.17 to 4.22)a 1.27 (0.61 to 2.67)
Quartile 4 5.99 (3.55 to 10.13)a 5.86 (3.03 to 11.36)a 2.60 (1.17 to 5.78)a
Urine KIM-1/creatinine
Per log increase 1.37 (1.12 to 1.69)a 1.44 (1.17 to 1.78)a 0.93 (0.71 to 1.22)
Quartile 1 Reference Reference Reference
Quartile 2 1.14 (0.71 to 1.82) 1.50 (0.83 to 2.70) 0.75 (0.38 to 1.48)
Quartile 3 1.32 (0.84 to 2.09) 1.44 (0.82 to 2.54) 0.69 (0.37 to 1.29)
Quartile 4 2.05 (1.31 to 3.19)a 2.22 (1.29 to 3.81)a 0.72 (0.38 to 1.36)
Urine IL-18/creatinine
Per log increase 1.22 (1.07 to 1.39)a 1.37 (1.14 to 1.65)a 1.15 (0.93–1.43)
Quartile 1 Reference Reference Reference
Quartile 2 1.18 (0.75 to 1.87) 1.22 (0.72 to 2.09) 0.87 (0.48 to 1.59)
Quartile 3 1.47 (0.94 to 2.30) 1.88 (1.08 to 3.28)a 0.95 (0.49 to 1.84)
Quartile 4 1.90 (1.22 to 2.98)a 2.85 (1.54 to 5.26)a 1.42 (0.71 to 2.86)
L-FABP/creatinine
Per log increase 1.77 (1.56 to 2.02)a 1.67 (1.41 to 1.97)a 1.07 (0.85 to 1.35)
Quartile 1 Reference Reference Reference
Quartile 2 1.08 (0.63 to 1.86) 1.00 (0.53 to 1.89) 0.74 (0.36 to 1.52)
Quartile 3 2.61 (1.59 to 4.29)a 2.50 (1.36 to 4.59)a 1.17 (0.57 to 2.42)
Quartile 4 5.22 (3.21 to 8.51)a 3.80 (2.07 to 6.96)a 0.81 (0.36 to 1.86)
Model 1 was adjusted for demographics, treatment, country, diabetes, smoking, graft vintage, donor, BP, lipids, BMI, and eGFR. Model 2 was adjusted for de-
mographics, treatment, country, diabetes, smoking, graft vintage, donor, BP, lipids, BMI, eGFR, and urine ACR.
aChi-squared test: P,0.05.
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have biased our results toward the null. This was a clinical trial
study population enrolling those with serum homocysteine level
above a certain cutoff, and there was a relatively high proportion
of living donor transplants; therefore, our results may not be
generalizable to all KTRs. Finally, there needs to be some caution
takenwhencomparingabsolutebiomarkerconcentrationsacross
studies that used different platforms and assays.
In conclusion, elevations in baseline urine injury bio-
markers NGAL, KIM-1, and IL-18 were significantly but
differentially associated with a higher risk of long–term car-
diovascular events, graft failure, and all-cause mortality, in-
dependent of known risk factors, including albuminuria.
Elevations in these urine biomarkers may signal some dimen-
sion of kidney disease or systemic disease that contributes to
adverse outcomes. Additional studies are needed to explore the
possible mechanisms to explain these findings.
CONCISE METHODS
Study Population
This report is a post hoc analysis of the FAVORIT Trial (clinicaltrials.
gov: NCT00064753), a multicenter, double–blind, randomized, con-
trolled clinical trial conducted to determine whether lowering
Figure 4. Cumulative incidence of all-cause mortality was greater among participants in the highest quartile of each urine injury
biomarker. Cumulative incidence of all-cause mortality by quartiles of (A) urine NGAL/creatinine, (B) urine KIM-1/creatinine, (C) urine
IL-18/creatinine, and (D) urine L-FABP/creatinine in a random subcohort (n=489).
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homocysteine levels with vitamin therapy reduced the rate of pooled
arteriosclerotic cardiovascular outcomes. The FAVORIT Study protocol
was approved by the Institutional Review Boards at the participating
institutions, and all participants provided written informed consent.
The design of the trial and the primary results have been described
in detail elsewhere.54–56 In total, 4110 KTRs were enrolled from
August of 2002 to January of 2007 and randomized to either a stan-
dard multivitamin with high doses of folic acid, vitamin B6, and
vitamin B12 or a multivitamin containing low doses of vitamin B6
and vitamin B12 with no folic acid. Men and women ages 35–75 years
old whowere at least 6months postkidney transplant were enrolled at
30 transplant centers in the United States, Canada, and Brazil. Entry
criteria included elevated serum homocysteine level ($11mmol/L for
women and$12mmol/L formen) and stable kidney function defined
by an estimated creatinine clearance $30 ml/min in men and
$25 ml/min in women. Follow-up contacts occurred every 6 months
through January 31, 2010 to obtain study-related outcomes through
June 24, 2009. The primary outcome was pooled incident or recurrent
CVD events. Graft failure and all-cause mortality were secondary out-
comes. As reported previously, there was no significant difference be-
tween treatment groups for primary or secondary outcomes.57
Urine Injury Biomarkers
Urine NGAL, urine KIM-1, urine IL-18, and urine L-FABP were
measured at a single laboratory at Cincinnati Children’s Hospital in
previously unthawed urine samples obtained at baseline and stored at
280°C. All assays were performed in June of 2013. The urine NGAL
ELISA was performed using a commercially available assay (NGAL
ELISA Kit 036; Bioporto, Grusbakken, Denmark) that specifically
detects human NGAL.58 The intra–assay coefficient of variation
(CV) was 2.1%, and interassay CVwas 9.1%. The urine KIM-1 ELISA
was constructed using commercially available reagents (Duoset
DY1750; R&D Systems, Inc., Minneapolis, MN) as described previ-
ously.59 Intra- and interassay CVs for KIM-1 were 2% and 7.8%,
respectively. Urine IL-18 and L-FABP were measured using commer-
cially available ELISA kits (Medical & Biologic Laboratories Co., Na-
goya, Japan and CMICCo., Tokyo, Japan, respectively). CVs for IL-18
and L-FABP were 7.3% and 6.1% (interassay) and 7.5% and 10.9%
(intra-assay), respectively. There were 128 participants whose sam-
ples were below the lower limit of detection (LLD; 10.3 pg/ml) for
IL-18 and 19 below the LLD (3 ng/ml) for L-FABP. For these partic-
ipants, values halfway between zero and the LLDwere assigned. Urine
creatinine was assayed using the modified Jaffe method. Intra-assay
CV was 2%, and interassay CV was 4%.
To correct for the effects of urine concentration and dilution, all
biomarker levels were standardized by urine creatinine concentration in
ourmain analysis. Because of the skewed distribution, urine biomarker/
urine creatinine was log transformed. To avoid assumptions of linearity,
biomarkers were modeled in quartiles as well as continuously.
Study Outcomes
Three outcomes were considered in our analysis: adjudicated CVD
events, graft failure, and all-cause mortality. The CVD outcome was a
compositeof cardiovasculardeath,myocardial infarction, resuscitated
Table 5. Unadjusted and adjusted HR estimates for risk of all-cause death according to urine biomarker (n=848 participants)
Urine Biomarker Unadjusted HR (95% CI) Model 1 HR (95% CI) Model 2 HR (95% CI)
Urine NGAL/creatinine
Per log increase 1.38 (1.25 to 1.53)a 1.55 (1.36 to 1.76)a 1.44 (1.26 to 1.65)a
Quartile 1 Reference Reference Reference
Quartile 2 1.93 (1.25 to 2.97)a 2.19 (1.27 to 3.81)a 1.98 (1.13 to 3.45)a
Quartile 3 1.78 (1.15 to 2.73)a 1.73 (0.96 to 3.11) 1.55 (0.85 to 2.80)
Quartile 4 3.26 (2.15 to 4.95)a 4.08 (2.32 to 7.18)a 3.12 (1.73 to 5.64)a
Urine KIM-1/creatinine
Per log increase 1.53 (1.28 to 1.83)a 1.44 (1.16 to 1.78)a 1.29 (1.03 to 1.61)a
Quartile 1 Reference Reference Reference
Quartile 2 1.21 (0.79 to 1.86) 1.19 (0.71 to 2.02) 1.03 (0.60 to 1.74)
Quartile 3 1.64 (1.08 to 2.48)a 1.56 (0.93 to 2.60) 1.32 (0.79 to 2.21)
Quartile 4 2.51 (1.69 to 3.75)a 2.33 (1.41 to 3.86)a 1.76 (1.05 to 2.93)a
Urine IL-18/creatinine
Per log increase 1.21 (1.07 to 1.36)a 1.35 (1.14 to 1.61)a 1.25 (1.04 to 1.49)a
Quartile 1 Reference Reference Reference
Quartile 2 0.98 (0.65 to 1.46) 1.04 (0.62 to 1.74) 0.93 (0.55 to 1.57)
Quartile 3 1.25 (0.84 to 1.85) 1.85 (1.11 to 3.11)a 1.55 (0.91 to 2.65)
Quartile 4 1.72 (1.17 to 2.53)a 2.31 (1.30 to 4.08)a 1.77 (0.98 to 3.17)
Urine L-FABP/creatinine
Per log increase 1.33 (1.18 to 1.49)a 1.31 (1.14 to 1.51)a 1.12 (0.94 to 1.35)
Quartile 1 Reference Reference Reference
Quartile 2 0.98 (0.65 to 1.49) 0.78 (0.44 to 1.36) 0.69 (0.39 to 1.21)
Quartile 3 1.47 (0.99 to 2.19) 1.11 (0.66 to 1.86) 0.84 (0.49 to 1.43)
Quartile 4 1.93 (1.29 to 2.88)a 1.55 (0.93 to 2.57) 0.85 (0.47 to 1.53)
Model 1 was adjusted for demographics, treatment, country, history of CVD, diabetes, smoking, graft vintage, donor, BP, lipids, BMI, and eGFR. Model 2 was
adjusted for demographics, treatment, country, history of CVD, diabetes, smoking, graft vintage, donor, BP, lipids, BMI, eGFR, and urine ACR.
aChi-squared test: P,0.05.
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sudden death, and stroke. Each of these outcomes was centrally
reviewed and adjudicated by the FAVORIT Clinical Endpoints
Committee.54–57 The same committee also reviewed medical records
for occurrence of unstable angina and urgent coronary revasculari-
zation procedures to identify additional patients with myocardial in-
farction. Graft failure was defined as initiation of dialysis ascertained
by local study staff. Study staff also identified deaths from review of
medical records, regular participant contact, and contact with family.
For each outcome, participants were censored at either the time of last
follow-up visit or the end of study period. For the outcomes of CVD
and graft failure, participants were also censored at time of death.
Covariates
At timeofstudyenrollment(baseline),demographiccharacteristics (age,
sex, race, and country of origin [United States, Canada, or Brazil]);
smoking status (current, former, or never); past medical history by self-
report (baseline CVD and diabetes mellitus); transplant characteristics
(living donor kidney and time since transplant); physical examination
findings (body mass index [BMI] and systolic and diastolic BPs); and
laboratory measurements (total cholesterol, HDL cholesterol, and
triglycerides) were obtained. Race was recorded as white, black, or
other, including mixed race. LDL cholesterol was estimated using the
Friedewald equation at triglyceride levels,400 andmeasureddirectly in
82 participants with triglyceride levels.400mg/dl. Baseline BPwas the
average of twomeasurements. Diabeteswas defined by the use of insulin
or oral hypoglycemic medications or participant self-report. Prior his-
tory of CVD was determined by self-report at baseline and included
prior myocardial infarction, coronary artery revascularization, stroke,
carotid arterial revascularization, abdominal or thoracic aortic aneu-
rysm repair, and/or lower extremity arterial revascularization or ampu-
tation above the ankle. BMI was calculated using the formula weight
(kg)/height (m)2. GFR was estimated from serum creatinine using the
Chronic Kidney Disease Epidemiology Collaboration 2009 equation.60
Serumcreatininewasmeasuredusing an alkaline picrate kineticmethod
on an Olympus AU 400e (Olympus America Inc., Center Valley, PA)
instrument that was calibrated to an isotope dilutionmass spectrometry
traceable standard.Urine albumin and creatinineweremeasured in spot
urine samples to calculate urine ACR. Urine albumin was measured
using an immunoturbidimetric assay. Intra-assay CV was 2%, and in-
terassay CV was 4%.
Study Design
To evaluate the association between urine kidney injury biomarkers
and outcomes, we performed a case-cohort study. Both patients and
nonpatients are drawn from the entire cohort, with patients identified
at study completion. Participants can contribute to more than one
type of case; for example, one participant can be included because of
bothCVDdisease and death.Members of the subcohort are randomly
selected from the entire cohort and can include individuals who are
also selected as patients. After excluding 104 participants withmissing
urine samples at baseline (n=53) ormissing key covariates (n=51), all
patients with cardiovascular events (n=291), graft failure (n=257),
and all-cause mortality (n=359) were included. We also sampled a
random subcohort (n=489) of FAVORIT Trial participants, with a
final study population of 1027 for this analysis.
Statistical Methods
Chi-squared test, ANOVA, and Kruskal–Wallis test were used as ap-
propriate to compare baseline data across quartiles of each urine in-
jury biomarker/urine creatinine in the random subcohort of 489
participants. We also reported characteristics of study participants
who did and did not have an outcome of interest. We generated a
Venn diagram to evaluate overlap among participants in the highest
quartiles of each urine biomarker. Among the random subcohort
participants, we then calculated the Spearman correlation coefficients
and generated scatterplots between eGFR, urine albumin, urine
NGAL, urine KIM-1, urine IL-18, and urine L-FABP.
Kaplan–Meier survival analysis was used to estimate the cumula-
tive incidence of each outcome among subcohort study participants
by quartile of each urine injury biomarker/urine creatinine. To take
into account the case-cohort study design, weighted Cox propor-
tional hazards regression61,62 was used to examine the association
between baseline urine injury biomarkers and time to study out-
comes. We examined the Schoenfeld residual plots from model 2
for each biomarker and outcome to check the proportional hazard
assumption (which did not seem to be violated). Models were ad-
justed for baseline age, sex, race, randomly assigned treatment, coun-
try fromwhich participants were recruited (United States, Canada, or
Brazil), diabetes, smoking, graft vintage, donor type, diastolic BP,
systolic BP, BMI, and eGFR. Models for the outcomes of CVD and
death were additionally adjusted for history of CVD and lipids. In a
final model, we further adjusted for urine ACR to test whether the
association of each urine injury biomarker with our outcome of in-
terest was independent of this established urine biomarker.
We performed three sensitivity analyses. First, we examined the asso-
ciation of each urine injury biomarker with risk of cardiovascular events
and all-cause mortality, excluding participants with prevalent CVD at
study entry. Second, we repeated our analyses without standardizing each
urine biomarker to urine creatinine concentration. Third, to evaluate for
possible competing risk,werepeatedourmultivariablemodels, examining
the association of each urine biomarker with risk of (1) cardiovascular
events or all-cause mortality and (2) graft failure or all-cause mortality.
All analyses were performed using SAS 9.3, SAS 9.4, and JMP.
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